Welcome to NEWTON 2
The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical study NEWTON2 (Protocol EG-01-1962-03) evaluating a new treatment for certain patients with aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that the blinded assessors at the clinical sites are well versed on the neurologic outcome assessments in this study. We are providing this online training course, assessment tools, and informational updates. Please see the menu for these materials.
Please contact the BIOS team with any questions. We look forward to working with you!
About NEWTON 2
The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is a multicenter, randomized, controlled, clinical trial evaluating Edge Therapeutics' novel formulation, EG-1962, compared to the current standard of care, oral nimodipine, to treat patients that have suffered an aneurysmal subarachnoid hemorrhage (aSAH) from a ruptured brain aneurysm. Results of the prior phase I/2 trial have been recently released; NEWTON 2 is the next step in this clinical development program. The Johns Hopkins Brain Injury Outcomes team will be supporting this trial by providing online and didactic training to the outcome assessors at the clinical sites.
Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, their lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm.